【摘要】 目的探讨早期使用重组人类促红细胞生成素(rHuEPO)防治早产儿贫血的疗效。方法将57例早产儿按入院次序分为治疗组30例、对照组27例。治疗组出生第7天给予每周rHuEPO 750 IU/kg,隔日1次,皮下注射,用药5周;对照组未用rHuEPO。两组早产儿均每天口服铁剂,按元素铁6 mg/(kg.d)计算,口服维生素E 25 mg/d,维生素C0.2 g/d。必要时输血。共观察6周。结果①两组早产儿生后血红蛋白(Hb)均渐下降,但治疗组程度较轻,经t检验,两组之间差异有高度显著性意义(P<0.01);②对照组有5例输血,而预防组仅1例输血,经χ2检验差异有高度显著性意义(P<0.01);③治疗后治疗组网织红细胞(Ret)较对照组显著升高,两组差异有高度显著性意义(P<0.01);④血清铁蛋白水平(SF)在用药期间治疗组明显低于对照组,治疗结束后,治疗组血清SF上升,两组比较差异无显著性意义(P>0.05)。结论早期使用rHuEPO能有效防治早产儿贫血,体内充足的铁储备是确保rHuEPO疗效的重要因素。更多还原

【Abstract】 Objective To investigate the preventive effect of recombinant human erythropoietin(rHuEPO) on anemia in prematures.Methods 57 prematures were assigned to 2 groups according to their order of hospitalization.30 prematures received rHuEPO at the dose of 750 IU/kg/week injected intramuscularly every other day beginning one week after birth for 5 weeks,in addition to routine treatment;27 prematures received only routine treatment,consisting of vitamin E 25mg/d,vitamin C 0.2 g/d,element iron 6mg/kg·d and blood transfusion(if indicated).Results ① Hb decreased gradually after birth in both groups,but the decline was significantly slower in rHuEPO group than in control group(P<0.01).②The need of blood transfusion was significantly less in rHuEPO group(5 patients) than in control group(1 patient)(P<0.05).③ Reticulocyte count was significantly higher in rHuEPO group than in control group(P<0.01).④ Serum ferritin level was significantly lower in rHuEPO group than in control group when rHuEPO was injected(P<0.01),after rHuEPO was stopped,serum ferritin level increased in rHuEPO group and the differences between two groups became non-significant(P>0.05).Conclusion Early use of rHuEPO can effectively prevent and treat anemia in premature and reduce the need for blood transfusion.Sufficient iron reserve is the important factor for the efficacy of rHuEPO.更多还原